- Home
- CHRS vs BSII Comparison
CHRS vs BSII Comparison
Compare CHRS & BSII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- BSII
- Stock Information
- Founded
- CHRS 2010
- BSII 2024
- Country
- CHRS United States
- BSII Hong Kong
- Employees
- CHRS 235
- BSII N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- BSII
- Sector
- CHRS Health Care
- BSII
- Exchange
- CHRS Nasdaq
- BSII Nasdaq
- Market Cap
- CHRS 134.4M
- BSII 189.9M
- IPO Year
- CHRS 2014
- BSII 2024
- Fundamental
- Price
- CHRS $1.22
- BSII $10.02
- Analyst Decision
- CHRS Strong Buy
- BSII
- Analyst Count
- CHRS 4
- BSII 0
- Target Price
- CHRS $5.38
- BSII N/A
- AVG Volume (30 Days)
- CHRS 2.4M
- BSII 4.2K
- Earning Date
- CHRS 03-12-2025
- BSII 01-01-0001
- Dividend Yield
- CHRS N/A
- BSII N/A
- EPS Growth
- CHRS N/A
- BSII N/A
- EPS
- CHRS N/A
- BSII N/A
- Revenue
- CHRS $304,340,000.00
- BSII N/A
- Revenue This Year
- CHRS $2.47
- BSII N/A
- Revenue Next Year
- CHRS N/A
- BSII N/A
- P/E Ratio
- CHRS N/A
- BSII N/A
- Revenue Growth
- CHRS 44.19
- BSII N/A
- 52 Week Low
- CHRS $0.66
- BSII $9.86
- 52 Week High
- CHRS $2.87
- BSII $10.30
- Technical
- Relative Strength Index (RSI)
- CHRS 44.03
- BSII N/A
- Support Level
- CHRS $1.03
- BSII N/A
- Resistance Level
- CHRS $1.23
- BSII N/A
- Average True Range (ATR)
- CHRS 0.13
- BSII 0.00
- MACD
- CHRS -0.02
- BSII 0.00
- Stochastic Oscillator
- CHRS 38.89
- BSII 0.00
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About BSII Black Spade Acquisition II Co Class A Ordinary Share
Black Spade Acquisition II Co is a blank check company.